Infusion care

Is home infusion right for every patient? Here’s who decides

4fgyyvwF4RbiP1Ge Photo05%E2%80%94nursecheckingtheIVsite leap 05 nurse checking iv site 4962x2439 image

By Sofia Shrestha, PharmD, CSP

Senior Director of Clinical Strategy, Leap

When patients learn they can receive their infusions at home, they might reasonably ask: Can I start with home infusions?

For many patients, the answer is yes. For some, the answer is “not yet,” and the reasons are clinical ones.

Employers and consultants might wonder the same thing when they see a drug on Leap’s specialty drug list. However, whether a drug belongs on our list and where a patient receives it are separate decisions. Every drug earns its place on Leap’s list through clinical review, and the prescriber decides where each patient receives it. Between those two decisions sit drug-specific program conditions that help determine when home isn’t an option yet.

How a drug earns its place on Leap’s list

Each of the 300+ drugs on Leap’s specialty drug list has to meet two tests:

  • Sourceable: It’s available through Leap’s network of specialty pharmacies.
  • Serviceable: It’s appropriate for administration in the home or at an infusion center in the Leap Transparency Network.

The serviceable test belongs to Leap’s Clinical Governance Committee, a multidisciplinary group that reviews every drug before it’s added to the list. External physician, nursing, and pharmacy advisers provide the senior clinical judgment, and alongside members from clinical operations and specialty pharmacy relations, weighs whether the therapy can be coordinated and sourced in practice.

The review doesn’t end once a drug is added. Leap’s Clinical Governance Committee continues to review new evidence related to the drugs on its list, such as FDA safety communications and labeling changes. When new evidence calls for it, the committee can add safeguards, change a drug’s program conditions, or remove it from the list.

Three stakeholders in the home infusion decision

For members of plans that offer Leap, there are three decision-makers that inform home infusion decisions in different ways. 

  • The patient’s prescriber decides whether home is the right setting for a specific patient.
  • The patient decides whether to use Leap’s care coordination, since participation is optional.
  • Leap’s Clinical Governance Committee decides which drugs can be supported by Leap for in the home or an infusion center site, and under what conditions.

Leap Care Guides and the nurses that Leap partners with work within the decisions made by these three key groups. Care Guides coordinate the logistics based on guardrails/protocols set by the committee, and the nurses follow the prescriber-ordered protocol.

hUpGrLP5YSxBChNK three stakeholders home infusion decision 4962x2439 image

When the answer is “not yet”

Sometimes home isn’t the right place to start, even when a patient wants it to be. The Clinical Governance Committee sets the program conditions each drug carries on Leap’s list, and some of those conditions apply before the question of home is ever on the table. 

Some conditions come from a drug’s FDA labeling or its Risk Evaluation and Mitigation Strategy (REMS), an FDA safety program that can limit where a drug is given. Others are set by the committee.  

A drug may require a first dose in a controlled setting, defined monitoring during the infusion, or enrollment in a REMS program. When one of those conditions applies, home isn’t offered for that dose.

LCMogJWYHhuD2 Wi Whatchangeswheninfusionmoveshome%E2%80%944962%C3%972439%2C300PPI home infusion changes 4962x2439 image

Why first doses get a closer look

First doses carry a different risk than later ones, in part, because there hasn’t yet been a chance to see how a patient reacts. In a study I co-authored on Ocrevus, a multiple sclerosis therapy, initial doses were three times more likely than maintenance doses to be associated with an infusion-related reaction, regardless of where the infusion took place. 

Each drug carries its own risk profile, so those findings apply to Ocrevus specifically. Still, the pattern is one reason a controlled-setting first dose is one of the conditions the committee can attach to a drug.

The prescriber decides where each patient starts

Every treatment plan starts with the prescriber, and the prescriber stays in charge of the patient’s medical decisions. The Infusion Nurses Society (INS), which publishes standards of practice for infusion nursing in the U.S., calls for infusion risks to be assessed before a patient begins home infusion. 

Prescribers weigh factors such as:

  • Treatment history: Which medicines the patient has received before and how well they tolerated them.
  • Other health conditions: Anything that could raise the patient’s risk, such as heart or lung disease, a weakened immune system, or a high risk of falls.
  • Reaction history: Whether the patient has had a reaction to an infusion or another medication.
  • Home setup: Electricity, clean water, a way to keep medication cold, and a suitable indoor space for the infusion.
  • Support nearby: Whether a caregiver can be present and how far the patient lives from an emergency room.

In recent conversations I’ve had with oncologists about home infusion, many are open to it when skilled nurses administer the treatment, clear safety protocols are in place, and the prescriber hears back about how each treatment went. 

gQi65w6YwAmJy0 B prescriber factors where care starts 4962x2439 image

Where care can start instead

When care starts outside the home, it can take a few forms:

  • Start in a clinic, then move home. A patient may receive a first dose, or first few doses, at the prescriber’s office before moving home.
  • Start at a nearby infusion site. Some patients are a good fit for one of Leap’s 300+ LTN sites. For a patient used to traveling hours to treatment, a site within Leap’s network may reduce drive time considerably. The patient can stay there or move home when the prescriber decides home is a good fit.
  • Revisit later. Some patients come back to the question once their response to the drug is established.

Home is one of several settings where Leap coordinates care. When a patient does move home, the same Care Guide typically stays with them, so the transition doesn’t mean starting over with someone new.

Who’s with the patient on infusion day

One of the most common misconceptions I hear, from patients and providers alike, is that home infusion leaves the patient on their own. That’s not the case with Leap.

Leap Care Guides coordinate care by navigating prior authorization within the patient’s health plan, coordinating with the prescriber’s office, and scheduling appointments. Our Care Guides are required to have a clinical background in providing care coordination. They are a collection of highly qualified individuals who include nurses and PharmDs.

On infusion day, a licensed registered nurse trained in infusion is in the home, administers the drug, and stays with the patient for the full infusion. Patients don’t start their own IV or access their own port. Leap requires that the nurses and agencies it partners with maintain a defined set of requirements:

  • Licensure: Every nurse in the Leap-partner network is licensed, infusion-trained, and clinically experienced.
  • Emergency training: Every nurse holds basic life support (BLS) and advanced cardiovascular life support (ACLS) certification.
  • Specialty training: Leap recommends certifications in infusion nursing (CRNI), vascular access (VA-BC), oncology nursing (OCN), and immunoglobulin therapy (IgCN).
  • Accreditation: Partner agencies are accredited by the Joint Commission, the Accreditation Commission for Health Care (ACHC), or an equivalent body.

Nurses are trained to recognize and manage infusion reactions and to follow established escalation protocols. 

What this means for benefits leaders

Moving members’ infusion care closer to home doesn’t require trading away clinical judgment. Every drug earns its place on Leap’s list through clinical review, and the prescriber decides where each patient receives it. The committee’s protocols decide when home waits, and nurses apply those protocols at every infusion.

If you’re weighing how many of your members could be good candidates, start with your own claims data. An impact analysis shows which of your members are on drugs Leap covers and what those encounters cost today.

oaQ8qbyuicqAMd4i AbouttheAuthor%E2%80%94SofiaShrestha%2Cnavycard 4962%C3%972439%2C300PPI about the author sofia shrestha navy 4962x2439 image

About the author

Sofia Shrestha is the Senior Director of Clinical Strategy at Leap. With extensive experience in managing complex pharmacotherapies for specialty and rare diseases, she brings a patient-centered approach to specialty care. Her diverse experience spans specialty pharmacy, home infusion, and ambulatory care, which she draws on to lead Leap's innovative pharmacy programs.

Share this post

More insights

uGsQNuRFuKAhTzKX benefits leader a reviewing report image
Education

Your guide to J-codes in medical billing, and what they can hide

An employer’s specialty trend was running at double digits, driven largely by therapies like Ocrevus...

Read article
gr 7yJaj1xLjiPDQ inside nurseadjustingIVdripforseniorpatientathome image
Education

Want to increase member participation in a specialty medicine solution? Reducing or waiving cost share is a good start.

One employee at a self-funded employer received Gammagard infusions twice a month for a rare autoimm...

Read article
A2LILi0roy6lnpj7 task export 6 image
Education

6 specialty medicine trends for 2027 and what they mean for benefits leaders

If it feels like specialty medicine is changing faster than your benefits strategy can keep up, that...

Read article
qmQqiddpjKSpw85s HRprofessional%E2%80%94intheoffice hr professional 3 office image
Education

Healthcare point solutions: What they are and 5 questions when evaluating them

If every healthcare point solution delivered the return in its sales deck, employer health costs wou...

Read article
XC0BuEWYGds6rfBI WeInfusepartnershipbloggraphic PNG%2C4962%C3%972439%2C300PPI 1 image
News

Leap expands specialty infusion network with WeInfuse collaboration

Leap is expanding its employer specialty infusion network through a new collaboration with WeInfuse,...

Read article
mIVvKbrIeVcspajE Spring Fall couplesittingtogetherongardenbenchwithcoffee image
Insights

Infusion vs. injection: Breaking down the basics of these two specialty therapies

In 1995, there were about 30 specialty drugs on the market. Today, there are nearly 1,000, and rough...

Read article
EJGfZMLy5m1bnieu inside closeupivdripformingdropletinhospital image
Insights

Let's blow up the buy-and-bill drug model: How it works and what it costs employers

Twice a year, a member with multiple sclerosis (MS) sits down for an Ocrevus infusion. The drug is t...

Read article
aVrzVnNYClf9oxJK Leap MS image
Insights

The real cost of MS infusion therapy and how a better member experience can bring down costs

For two years, Maria drove two hours each way for her multiple sclerosis (MS) treatment. Every appoi...

Read article
Oncology biosimilars market
Education

The emerging oncology biosimilars market and how employers can prepare.

A member who starts Keytruda today will likely organize the next two years of their life around it. ...

Read article
WWqCZQJnAGmcLNW4 Summer couplesittingtogetheronporchswing image
Education

Is home infusion safe for immunoglobulin therapy? What patients should know

Whether you've just been prescribed immunoglobulin (Ig) therapy, or you've been getting it at a clin...

Read article